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Abstract
Background: Urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), of the bladder is the most
common neoplasm affecting the canine urogenital system. To facilitate study of the disease in vitro, cell line models
have been established from primary tumor biopsies. Their resemblance to the primary disease, however, has not been
well defined. In the present study, we evaluated five canine UC cell lines via oligonucleotide array comparative genomic
hybridization (oaCGH), fluorescence in situ hybridization (FISH), and gene expression analysis.
Results: Comparison of genome wide DNA copy number profiles of the cell lines with primary biopsy specimens
revealed redundancies in genomic aberrations, indicating that the cell lines retain the gross genomic architecture
of primary tumors. As in the primary tumors, gain of canine chromosomes 13 and 36 and loss of chromosome 19
were among the most frequent aberrations evident in the cell lines. FISH analysis revealed chromosome structural
aberrations, including tandem duplications, bi-armed chromosomes, and chromosome fusions, suggesting genome
instability during neoplastic transformation. Gene expression profiling highlighted numerous differentially expressed
genes, including many previously shown as dysregulated in primary canine UC and human bladder cancer. Pathway
enrichment analysis emphasized pathways suspected to be at the crux of UC pathogenesis, including xenobiotic and
lipid compound metabolism.
Conclusions: These data support valid use of the canine UC cell lines evaluated by confirming they provide an
accurate and practical means to interrogate the UC at a molecular level. Moreover, the cell lines may provide a
valuable model for furthering our understanding of aberrant metabolic pathways in UC development.
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Background
Urothelial carcinoma (UC), also referred to as transitional
cell carcinoma, is the most common bladder neoplasm in
the dog [1]. While precise lifetime risk and incidence
numbers in pet dogs are unknown, UC is estimated to
affect more than 20,000 dogs each year in the United
States [2]. Due to the uncomfortable and potentially fatal
consequences associated with a rapidly growing blad-
der tumor, the diagnosis of UC conveys a guarded
prognosis and evokes considerable dog owner concern
[3]. Additionally, over 90 % of canine bladder tumors
are invasive with metastatic potential; approximately
20 % of canine patients show overt metastases at the
time of diagnosis and over 60 % at death [2]. The
devastating clinical course of disease, combined with
a high rate of metastasis, emphasizes a need for early
detection of the tumor. With improved detection and
a better understanding of the disease, therapeutics
may prove more efficacious, extend patient survival,
and improve quality of life.
Previous studies have shown that the genomic landscape
of canine UC is highly aberrant, with recurrent chromo-
some copy number aberrations affecting gene dosage on,
most notably, canine chromosomes (CFA) 13, 19, and 36
[4]. In addition, overwhelming breed predispositions
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suggest the risk for UC development is at least partially
genetic. The inbred history of purebred dogs, resulting in
reduced levels of genetic variation and enrichment in
breed-associated loci, provides a biologic basis for breed
susceptibility [5]. Scottish terriers, for example, are
diagnosed with UC 20 times more frequently than the
average of all breeds, and Beagles, Shetland sheep-
dogs, Wire hair fox terriers, and West Highland white
terriers are reported to be affected three to five times
as frequently [1]. The uniquely homogenous genetic
population of purebred dogs makes the dog an excellent
model for teasing out genetics that are potentially import-
ant in cancers of the highly heterogeneous human popula-
tion. Previous studies also have found that canine UC
closely resembles that of the human counterpart, in histo-
pathological features, clinical behavior, and genomic aber-
rations, furthering the value of the dog to human
medicine [2, 6, 4].
In addition to genetic risk factors, UC is associated with
numerous environmental factors, including flea and tick
dips, obesity, pesticides, and cyclophosphamide treatment
[7–9]. While correlations of UC incidence with each of
these risk factors have been found, mechanisms of
carcinogenesis have yet to be elucidated. Problems in cyc-
lic compound metabolism have been proposed, but until
the mechanisms of UC development are elucidated, the
provision of effective prevention and treatment strategies
will remain challenging [10]. The study of potential
molecular drivers and therapeutic targets would be greatly
expedited by a biologically appropriate in vitro model.
Cell lines provide a useful in vitro model for the
study of disease. By facilitating characterization and
manipulation of all molecular facets without harming
the model animal, cell lines enable researchers to
evaluate highly experimental ideas and therapies. Al-
though canine UC cell lines have previously been
established for such use [11], their resemblance to the
primary tumor in the context of molecular behavior
and genomic landscape has yet to be thoroughly eval-
uated. Affirming the cell lines recapitulate molecular
characteristics of the primary tumor would increase
their clinical predictive value and enhance their sig-
nificance in translational studies.
In the present study, we investigated the molecular
profile of five canine UC cell lines with oligonucleotide
array comparative genomic hybridization (oaCGH) and
fluorescence in situ hybridization (FISH). Clinical rele-
vance of findings was validated by comparison of
oaCGH profiles of cell lines with those of primary tumor
samples, which showed conservation of major genomic
aberrations in both sample cohorts. Subsequent gene ex-
pression profiling quantified mRNA from copy number
neutral and aberrant regions of the genome. KEGG
pathway and gene ontology (GO) analysis demonstrated
that genes involved in lipid metabolism and cell cycle
regulation were enriched among genes differentially
expressed between neoplastic cell lines and healthy
urothelium, highlighting a potential pathogenesis that is
relevant to known risk factors. Our results affirm that
the canine UC cell lines are genomically similar to the
primary tumor, providing a relevant in vitro model for
study of the molecular mechanisms of disease.
Methods
Case collection
Five tumor cell lines (Table 1) were established from
pathologically-confirmed UC in dogs who were evalu-
ated and treated at the Purdue University Veterinary
Teaching Hospital. The biopsies used to establish the
cell lines were collected via cystoscopy or at necropsy.
All samples were obtained with informed pet owner
consent and under an approved IACUC protocol. Once
established, cells from each line were cryopreserved at
various passages.
Control samples for expression analysis (healthy urothe-
lium) were collected during necropsy of dogs with no
clinical or histopathological signs of disease at North
Carolina State University College of Veterinary Medicine.
After collection, bladder tissue was stored in transport
media (RPMI media supplemented with 10 % fetal bovine
serum (FBS) until sample processing (<1 h). Samples were
split in half: one half was fixed in 10 % neutral buffered
formalin (NBF) before paraffin-embedding (FFPE) to en-
able pathologic evaluation, and the second half was used
for urothelial cell isolation. FFPE samples were sectioned
and stained with hematoxylin and eosin (H&E) for review
Table 1 Characteristics of five canine UC cell lines
Cell Line ID Initial passage Breed Sex Average chromosome # Specific structural changes
K9TCC-PU-An (TCC2) p3 Scottish Terrier FS 131.6 TD(10,36), t(36;38),f(13;13)
K9TCC-PU-In (TCC6) p1 German Shepherd FS 103.3 TD(10,36), f(13;13)
K9TCC-PU-Mx (TCC5) p5 German Shepherd FS 134.6 TD(10,36)
K9TCC-PU-Sh (TCC4) p6 Collie FS 105.5 TD(36,38), t(36;38),
K9TCC (TCC3) p14 Mixed Breed FS 76.2 TD(10)
Five cell lines, derived from primary biopsy specimens, were evaluated in this study. Cell line identifier, initial passage number, breed, and sex (FS female spayed)
are shown. Chromosomes from metaphase spreads (n = 30) of each cell line were counted to determine an average chromosome number. Recurrent structural
changes identified by FISH evaluation are shown (TD tandem duplication, t translocation, f fusion)
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by a board certified veterinary pathologist. All control
samples were found to be histopathologically normal prior
to use in subsequent protocols. Urothelial cells were iso-
lated by scraping the bladder mucosa three times with a
glass slide and rinsing with 1x phosphate buffered saline
(PBS), as described previously [12]. Urothelial scraping
was performed in order to minimize contamination of
urothelium by submucosal tissue layers. Cell scrapings
were then analyzed under phase contrast to determine the
proportion of epithelial cells to contaminating mesenchy-
mal cells. Over 90 % of isolated cells were confirmed to be
epithelial.
Culture preparation
Cells from each of the five lines were cultured in DMEM/
F12 without glutamine (Mediatech, Manassas, VA) and
supplemented with 10 % FBS (Mediatech), 1 % Glutamax™
(Life Technologies, Carlsbad, CA), and 0.6 % Primocin™
(InvivoGen, San Diego, CA) to confluence, passaging
when confluent. For each line, cells from the same flask
were split into three aliquots and used simultaneously for
chromosome preparation, DNA isolation, and RNA isola-
tion. Four of the cell lines (K9TCC-PU-An, K9TCC-PU-
In, K9TCC-PU-Mx, K9TCC-PU-Sh) were available as low
passage (<p7) and so were harvested at an earlier (<p10)
and later (>p16) passage to evaluate genomic evolution
during culture. One cell line (K9TCC) was available only
from p14 and so was harvested at p16 only.
oaCGH
DNA from each cell line ("test") was isolated using a
DNeasy Kit according to manufacturer’s recommenda-
tions (Qiagen, Valencia, CA). Purified DNA was verified
to be of high molecular weight and purity by agarose gel
electrophoresis and spectrophotometry (Nanodrop™
1000, Thermo Fisher Scientific, Wilmington, DE;
260:230 > 2.0 and 260:280 > 1.8). Since all five cell lines
were female, a single female "reference" mix was gener-
ated by combining equimolar quantities of DNA ex-
tracted from ten different, healthy female dogs of
various breeds (QIAmp DNA Midi Kit, Qiagen). Isolated
DNA was labeled using the Genomic DNA Enzymatic
Labeling Kit (Agilent Technologies, Santa Clara, CA) as
described previously [4, 13]. Fluorescently labeled test
and reference DNA samples were hybridized to Canine
G3 Sureprint 180,000 feature oaCGH arrays (Agilent,
AMADID 025522) for 40 h, as described previously
[13, 14]. Arrays were scanned at 3 μm (Agilent,
Model G2505C) and data extracted with Feature Ex-
traction software (v10.9 Agilent) using the canFam2 genome
build. CGH results were analyzed using the FASST2 algo-
rithm in Nexus Copy Number (Biodiscovery, Hawthorne,
CA). After aberration detection, cell lines and primary
tumors were clustered based on aberrations using a
complete linkage hierarchical clustering algorithm by
Nexus Copy Number (Biodiscovery).
Genomic regions likely to be central to tumorigenesis
were pinpointed by the Genomic Identification of
Significant Targets in Cancer (GISTIC) algorithm in
Nexus Copy Number, which identifies regions unlikely
to be aberrant by chance when taking aberration fre-
quency and amplitude into account [15]. A G-score is
computed to reflect the frequency and amplitude of the
aberration, while a q-value suggests the likelihood (prob-
ability) of that aberration occurring by chance when
looking at the overall aberration pattern throughout the
genome. Lastly, aberrations in early and late passage cell
lines were compared using the “Comparisons” tool in
Nexus, using the early passage as baseline (p = 0.05,
differential threshold = 1 %).
Primary tumor oaCGH data
Previously published oaCGH data from 31 primary ca-
nine UCs was compared to cell line aberrations [4].
None of the cell lines used in the current study were de-
rived from any of the 31 primary tumors. Using Nexus
Copy Number, aberrations common to primary tumors
and cell lines were compared using the “Comparisons”
tool. Additionally, GISTIC analysis was repeated using
primary tumor aberrations.
Fluorescence in situ hybridization (FISH)
Cells were harvested using conventional methods of
colcemid-induced metaphase arrest (Life Technologies),
hypotonic (KCl) treatment (Life Technologies), trypsini-
zation (0.25 % trypsin, Mediatech), and fixation, as
described previously [16]. Fixed cell suspensions were
dropped onto clean glass slides and aged for three days
at room temperature prior to ethanol dehydration
(70 %/90 %/100 %) and storage at −80 °C.
Fluorescence in situ hybridization (FISH) was used to
validate and visualize copy number aberrations indicated
by oaCGH. Based on FASST2-called aberrations, 11
genomic regions were selected for FISH analysis: 10
aberrant regions of high frequency (gained/lost in at least
three cell lines) and one balanced region on CFA 11, se-
lected as a copy number neutral control (Log2 = 0)
(Table 2). Probe DNA was extracted from clones of the
CHORI-82 canine BAC library (http://bacpac.chori.org/
library.php?id=253) containing the regions of interest and
labeled with one of five spectrally-resolvable fluorochrome-
conjugated dNTPs as described previously [17]. Multicolor
FISH reactions were performed first on DAPI-stained
metaphase chromosome preparations of clinically healthy
dogs to validate the unique and precise cytogenetic loca-
tion of each probe, as described previously [16]. Verified
probes were hybridized to metaphase preparations of each
cell line and visualized by using an Olympus BX61
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fluorescent microscope (Olympus, Center Valley, PA)
equipped with appropriate single pass filters. Cells (n ≥ 30)
exhibiting good chromosome separation were selected for
assessment of numerical and structural organization and
were counted to determine a) total chromosome number
and b) number of signals for each fluorochrome (sequence
of interest).
Using Log2 ratios ascertained by oaCGH and also de-
duced from single locus-BAC probe probe enumeration,
correlation coefficients were derived. To calculate the
Log2 ratio, the average copy number of the aberrant
locus was divided by the average copy number of the
CFA11 neutral locus of each cell line. A Log2 of the re-
sultant value was calculated and used as the FISH-
derived Log2 for each copy number-aberrant locus. Add-
itionally, a Mann–Whitney U test (two-tailed, p < 0.05)
was performed using JMP Professional Statistical Soft-
ware (v. 11, SAS, Cary, NC) to compare mean Log2
ratios from both methods.
Gene Expression
RNA was extracted from cultured cells or control
urothelial cells using the RNeasy Plus Mini Kit (Qiagen).
RNA was immediately isolated from the healthy, fresh
urothelial cells to minimize alterations in post-mortem
and post-collection gene expression. RNA purity and
integrity was assessed using spectrophotometry (Nano-
drop) and a 2100 BioAnalyzer (Agilent), respectively.
Samples with 260:230 and 260:280 > 2.0 and RIN > 8.0
were used for microarray analysis and qRT-PCR valid-
ation. RNA was labeled using the Quick Amp Labeling
kit (Agilent). Purified RNA probes were hybridized to a
one-color expression microarray (Agilent SurePrint G3
Canine 4x44k Expression Array). Arrays were scanned at
3 μm (Agilent, Model G2505C). Analysis was performed
using the GeneSpring advanced platform (Agilent,
v.11.5, 2011) and Nexus Expression (BioDiscovery, v.2.0,
2010). Prior to expression normalization, compromised
probes were removed from analysis in GeneSpring, in-
cluding features which were non-uniform, saturated, or
population outliers. Normalized signal values were ob-
tained by log transformation, followed by 75th percentile
shift normalization and baseline shift to median of all
samples. Normalized signal values (NS) were compared
between RNA isolated from the cell lines and from
urothelium of two histologically confirmed healthy dog
bladders to determine the fold change in expression
(NScell_line ÷ NScontrol_average = relative fold changegene).
Significantly over- and underexpressed genes in demon-
strated a ± 2-fold change in gene expression in the cell
lines relative to the average of control bladders. The
resulting gene expression profiles of cell lines and
healthy control urothelium were clustered using an
agglomerative, unsupervised hierarchical clustering algo-
rithm in Nexus Expression (Biodiscovery).
In preparation for qRT-PCR validation of array data,
primers were designed for a stably expressed control
gene (RPL32) and for a gene within each of the loci
assessed by FISH and dysregulated according to the ex-
pression array. Ct values for RPL32 were within 0.7 Ct
among all cell lines and controls (standard deviation =
0.23), validating its use as a reference gene. Ct Primer
template specificity was confirmed by agarose gel elec-
trophoresis of PCR products (single product) and primer
melt curve analysis (single peak). An efficiency curve
based on five ten-fold dilutions was constructed to
evaluate the performance of each primer pair. Primers
with efficiency between 90-110 % and linear correlation
coefficients over 0.95 were selected for qRT-PCR ana-
lysis (seven aberrant regions of interest plus a control
gene, Table 3). cDNA was created using the QuantiTect
Reverse Transcription Kit (Qiagen). The Quantifast
Table 2 Regions chosen for FISH validation of oaCGH
BAC address Region probed Fluorochrome oaCGH-called aberration
326 N03 chr1:35846825-36021610 Red Loss
307I06 chr6:49193262-49385361 Green Loss
326H08 chr10:13936488-14128322 Cy5 Amplification
126 F01 chr12:52174704-52401789 Gold Loss
186 J06 chr13:38344516-38552798 Aqua Gain
332 N02 chr19:31345273-31534341 Red Loss
313D22 chr21:5212350-5387435 Green Loss
307D14 ch33:5409680-5589439 Red Loss
199 F16 chr36:7057670-7276062 Cy5 Amplification
328D10 chr38:25164963-25365710 Gold Amplification
326 L05 chr11:20496757-20706739 Aqua Neutral
Ten BAC clones were selected to probe regions shown to be highly aberrant in the cell lines (>50 % penetrant). A copy number neutral region on CFA11 was
chosen as an internal control to ensure correct interpretation of relative locus copy number. The BAC address, genomic location (CanFam2.0 assembly), and
associated fluorochrome for each probe are shown
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SYBR Green qPCR Kit (Promega, Madison, WI) was
used for real time quantification of mRNA on an iCycler
iQ™ Real Time Detection System (Bio-Rad, Hercules,
CA). Fidelity was ensured by inclusion of no reverse
transcriptase and no template negative controls. A correl-
ation coefficient relating data from qRT-PCR and expres-
sion array was calculated using fold change values from
genes evaluated using both methods. Gene ontology (GO)
and pathway analysis was conducted on differentially
expressed genes (DEGs) using the online tool DAVID to
extract biological relevance from the data [18].
Results
Canine UC cell lines display recurrent chromosome copy
number and structural aberrations
Metaphase preparations from each of the five canine UC
cell lines revealed a high degree of aneuploidy, with an
excess of 100 chromosomes in four of five cell lines
(Table 1). Additionally, oaCGH profiles revealed specific
DNA copy number gains and losses across the genome
of each cell line (Fig. 1a). Highly recurrent aberrations
(>80 % frequency) involved loss of regions of CFA 1, 2,
5, 6, 9, 10, 12, 19, 20, 21, 22, 26, 28, 33, 34, and X, and
Table 3 Copy number aberrant genes analyzed by qRT-PCR
Gene Location Forward primer Reverse primer
RNPC3 chr6:50072550-50098045 5′-GGGGCGACCGGCCCTTCTA-3′ 5′-GACAGGACGCGCACCGACTG-3′
MDM2 chr10:13920606-13946580 5′-ACGGCAGAGAAAGCGCCACAAA-3′ 5′-GGCGTCCCTGTTGACTCACTG-3′
EIF2C2 chr13:38222456-38271623 5′-CAAAGGCAGTCCAGGTTCAT-3′ 5′-GGGCATCTGTTGGTCTGAGT-3′
RALB chr19:32842484-32862087 5′-GTGTTCTTGCTCTCCCCAAC-3′ 5′-TCCAAAACCTCCCAACAAAG-3′
CLNS1A chr21:24140052-24163815 5′-CCTGTGTCTCCGCGCTCCCTG-3′ 5′-GCCTCGGTCTCGGGCTGCTG-3′
STX19 chr33:4727847-4728760 5′-CTGCTATGTTCCGCCAATTT-3′ 5′-GCACTTCTTTTCCAGCAACC-3′
TAGLN2 chr38:25240217-25241796 5′-TGCGGACCTGGAGCAGATCCTG-3′ 5′-ACACAGCACCGTGCCATCCT-3′
RPL32 chr18:10198892-10204028 5′-ATGCCCAACATTGGTTATGG-3′ 5′-ATGCCCAACATTGGTTATGG-3′
The mRNA levels of genes located within seven regions of copy number aberration were evaluated by qRT-PCR. The targeted gene, genomic location (CanFam2.0
assembly), and primer pair utilized are shown
Fig. 1 oaCGH profiles of five canine UC cell lines recapitulates those seen in 31 primary tumors. Cell lines were analyzed via oaCGH at an early stage
(<p16) and aberrations called based on Log2 ratios relative to normal canine DNA (a). When compared with 31 primary tumors previously analyzed
(b), aberrations were shared between the two cohorts, validating the use of canine UC cell lines in genomic studies. When clustered by oaCGH
aberration profiles (c), the cell lines (astericked; TCC2 = K9TCC-Pu-An, TCC3 = K9TCC, TCC4 = K9TCC-Pu-Sh, TCC5 = K9TCC-Pu-Mx, TCC6 = K9TCC-Pu-In)
clustered among the primary tumors (no asterisk) rather than appearing as an outgroup, further showing their greater similarity to the primary tumors
than to one another and showing minimal effect of the culture environment on genome evolution
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gains of CFA 4, 5, 6, 8, 9, 10, 11, 13, 15, 16, 17, 27, 34,
and 36. Shared copy number losses present on CFA 2, 6,
10, 21, 26, and 28 and gains of CFA 6, 8, 10, and 13 were
observed in all five cell lines (100 %). High amplitude
aberrations (Log2 > 4) were noted on CFA10, 36, and 38,
suggesting DNA amplification in these regions. To iden-
tify regions differentially aberrant between early and
later passage cell lines, a “comparisons” analysis was
performed in Nexus Copy Number. The analysis showed
only three genomic regions where the aberration fre-
quency among the early and later passage cell lined dif-
fered by more than 1 %: CFA1q22, CFA2q24.1, and
CFA9q22.3 (p < 0.01). Although copy number neutral in
early cell line passages, later passages of the same cell
lines demonstrated a copy number gain.
Cell line oaCGH profiles were compared to those of
31 previously published primary tumors (Fig. 1b).
Hierarchical clustering of chromosome copy number ab-
errations among cell lines and primary tumors yielded a
dendogram in which there was no segregation between
the cell lines and primary tumors (Fig. 1c). Comparison
analysis of primary tumors and cell lines highlighted
only 17 regions, constituting less than 0.2 % of the gen-
ome (4.5 Mb), aberrant in either the primary tumors or
cell lines, while normal in the other (Additional file 1:
Table S1). GISTIC analysis of aberrations among pri-
mary tumors and cell lines showed that 71.4 % (five of
seven total GISTIC-identified regions) of specific cancer-
associated genomic regions aberrant in the cell lines
were similarly altered in the primary tumors, including
amplified regions on CFA10, 36, and 38 and gains of
CFA13 (Q-bound < 0.005, G-score > 5, Table 4). The
primary tumors were generally more aberrant, with 60
significant cancer-associated genomic regions identified.
Thus, GISTIC aberrations among cell lines represent
only 8.3 % of those in the primary tumor.
Chromothriptic-like events were noted throughout the
genome of all five of the cell lines, most notably on CFA
9 and 10 (>80 % of cell lines) (Fig. 2a). CFA 5, 10, 19, 35,
and 36 had an average of over five chromothriptic-
events per cell line, with CFA10 chromothriptic-like
events occurring an average of 10 times per cell line
(range = 1-20; Fig. 2b).
Targeted FISH analysis of genomic loci identified as aber-
rant by oaCGH confirmed the presence of abnormal DNA
copy number in individual cells and enabled enumeration
of exact copy number (Table 5). No significant difference
was observed among average oaCGH- and FISH-derived
Log2 ratios (Table 5, p > 0.56 overall, Mann–Whitney
U test), while correlation analysis showed a strong
correlation between FISH- and oaCGH-determined Log2
ratios (r = 0.91). FISH enabled appreciation of hyperdi-
ploid status in four of five cell lines (K9TCC-Pu-An,
K9TCC-Pu-In, K9TCC-Pu-Mx, K9TCC-Pu-Sh), with aver-
age total chromosome number among 30 enumerated
chromosome spreads ranging from 103 (K9TCC-Pu-In) to
134 (K9TCC-Pu-Mx) total chromosomes (Table 1). FISH
further allowed identification and visualization of several
recurrent structural aberrations involving interrogated
regions (Fig. 3), including tandem duplications, transloca-
tions, chromosome fusions, and bi-armed chromosomes
(Table 1). Tandem duplications were noted on CFA 10, 36,
and/or 38 in all five cell lines (Fig. 3a & c), coincident with
high level amplification indicated by the corresponding
oaCGH profiles. An excess of 30 copies of the targeted
locus of CFA 36 were noted in the K9TCC-PU-Mx line,
confirming the expected Log2 > 4. The region probed on
CFA 38 demonstrated a translocation to a position adja-
cent to the CFA 36 locus in two cell lines (K9TCC-PU-An
and K9TCC-PU-Sh). In K9TCC-PU-Sh, tandem duplica-
tions of CFA 36, juxtaposed with tandem duplications of
CFA 38, were present twice on a single aberrant chromo-
some structure (Fig. 3c). Additionally, centromeric fusion
of CFA 13, resulting in a bi-armed aberrant chromosome,
was noted in two lines (K9TCC-PU-An and K9TCC-PU-
In; Fig. 3b). Other aberrantly metacentric chromosomes
were noted in all five cell lines, affecting multiple
chromosomes.
Gene expression profiles of cell lines differ from those of
normal urothelium
When profiled alongside healthy urothelium, the UC cell
lines showed highly differential gene expression levels.
Of 43,803 probes on the array, 8,688 probes, represent-
ing at least 3,303 Ensembl-annotated canine genes,
displayed altered levels of expression with absolute fold
change greater than 2.0 when normalized and compared
to reference urothelium. Examples are shown in Table 4
and were selected based on the magnitude of fold
change and potential relevance to tumorigenesis.
Table 4 Regions implicated by GISTIC analysis represent regions
relevant to neoplasia
Genomic region Aberration Q-Bound G-Score
chr10:13,614,516-14,400,849 CN Gain 8.22E-06 9.606238
chr10:17,743,915-20,676,296 CN Loss 0.02737 7.847499
chr10:44,389,882-71,751,790 CN Gain 0.005379 5.952698
chr10:5,318,483-7,102,150 CN Gain 0.005379 5.990278
chr13:3,033,844-66,047,830 CN Gain 0.005379 5.576475
chr36:22,492,857-25,421,734 CN Gain 0.005379 5.578811
chr38:3,874,100-4,368,891 CN Gain 0.005379 5.403421
Minimum regions of shared aberration among cell lines are shown, as well as
the called aberration (CN copy number), Q-bound, and G-score. The G-score
reflects the frequency as well as magnitude of the aberration in the cohort,
while the Q-bound indicates significance. The most notable regions were
located on CFA10, CFA13 and 36; gains of CFA13 and 36 are of diagnostic
relevance in primary UC and were similarly aberrant in cell lines
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Hierarchical expression clustering confirmed a vastly
different expression landscape between tumors and
control urothelium, each recognized as a separate out-
group based on DEGs (Additional file 2: Figure S1).
qRT-PCR analysis of selected genes verified expression
array results. All seven genes analyzed for each of the
five cell lines had a direction of fold change in agree-
ment with the expression data, with log fold change ra-
tios calculated from qPCR results showing a very strong
correlation to expression array log fold change (r = 0.96,
Fig. 4). In addition, the magnitude of expression fold
change calculated by qRT-PCR correlated strongly and
positively with magnitude of copy number loss/gain, as
calculated by FISH and oaCGH (r = 0.76, Fig. 4).
Using the DAVID tool for gene ontology (GO) and
pathway analysis, DEG enrichment in functional pathways
was evaluated. Among underexpressed genes (1859 total),
the GO term “lipid metabolism” was the only GO term
enriched (p = 0.03) in our dataset, with 189 genes under-
expressed in the cell lines. Among overexpressed genes
(1444 total), “DNA replication, recombination, and repair”
was the most highly enriched term (p = 0.01), with 13
overexpressed genes. When evaluating all DEGs, “DNA
replication and repair” was the single most commonly
dysregulated functional ontology, represented by 10 % of
all cell line DEGs.
KEGG pathway analysis in DAVID highlighted four
pathways enriched for underexpressed genes: metabolism
of xenobiotics by cytochrome p450, glutathione metabol-
ism, drug metabolism, and fatty acid metabolism, resulting
in a KEGG pathway clustering of these pathways with an
enrichment score indicative of biological significance
(Bonferroni = 0.05, enrichment score = 2.34). Additionally,
3.7 % of genes with five-fold or greater expression than
normal urothelium (10 of 268) were involved in cell cycle
regulatory pathways (p = 0.0004), as were 1.8 % (26 of
1444) of all upregulated genes (p = 0.00003). DAVID
chromosome association analysis found 4.7 % of overex-
pressed genes (68 genes) were found on CFA 13 and 4.2 %
on CFA 10 (61 genes). Similarly, 3.6 % (66 genes) of
underexpressed genes were located on CFA 12 and 1.2 %
on CFA 19 (23 genes).
Discussion
Canine UC represents the most common genitourinary
cancer in dogs and, due to the aggressive nature of the
tumor, diagnosis conveys a guarded prognosis for the
patient [1]. To date, curative therapies are lacking for
A
B
Fig. 2 The cell lines demonstrate evidence of chromothriptic-like events in tumor evolution. Chromothriptic-like events were seen throughout
the genomes of all five cell lines, involving all but six chromosomes (a). The maximum average number of events on a single chromosome was
observed on CFA10, with ten chromothriptic-like events. CFA2, 5, 19, 20, 35, and 36 all showed an average of over four events (b). At least three
of the cell lines displayed chromothriptic-like events on CFA2, 5, 7, 9, 10, 18, 20, 27 and X. Thus, complex chromothriptic-like activity is a common
event in the UC cell lines, just as in primary tumors
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UC, which is likely due in part to delayed tumor diagno-
sis and the lack of knowledge about the molecular basis
of tumor pathogenesis. It is known, however, that canine
UC closely resembles prognostically unfavorable invasive
human UC, making research in canine bladder cancer
potentially valuable in improving the outlook for human
UC patients [6, 2, 1, 11]. As a result, a valid in vitro cell
line model would be advantageous to both species and
could potentiate investigation of more precise molecular
mechanisms involved in UC pathogenesis, including the
development of therapies to target them. Previously, five
canine UC cell lines were established for in vitro study
of the disease, and four of them retain tumorigenicity in
mice [11]. With the potential to facilitate translational
studies, care should be taken to determine that these cell
lines provide a high clinical predictive value. Our study
sought to evaluate: 1) the genomic similarity between
primary UC and cell lines, 2) the genomic integrity of
the cell lines over time, and 3) the gene expression land-
scape of canine UC cell lines.
Our results show that, although variation exists in the
frequency of copy number aberrations between the cell
lines and primary tumors, the most frequent copy num-
ber gains and losses are preserved in the cell lines,
specifically loss of regions of CFA 19, and gain of regions
of CFA 13 and 36 [4]. Among primary tumors, 100 % of
the canine UC cases possess at least one of these aberra-
tions, 94 % possess two, and 68 % possess all three aber-
rations, emphasizing the diagnostic potential of copy
number aberrations and a potentially critical role of
these chromosomes in tumorigenesis. Similarly, all five
cell lines had at least one of these aberrations (100 %),
four had at least two (80 %), and two had all three aber-
rations (40 %). When oaCGH-called aberrations among
the 31 primary tumors and five cell lines were clustered,
no cell line outgroup was seen, suggesting the cell lines
were more like primary tumors than one another other
and demonstrating a lack of culture artifact in their gen-
omic profiles. Thus, the cell lines maintain the valuable
aberrations of the primary tumor and provide an in vitro
tool with which to further investigate the significance of
these aberrations in canine UC.
The relevance of the gains on CFA13 and 36 are
further emphasized by GISTIC analysis. GISTIC ana-
lysis, which focuses on regions containing genes repeat-
edly implicated in neoplastic transformation and tumor
growth, highlighted only seven regions aberrant in the
cell lines: amplified regions on CFA10, 36, and 38 and
Table 5 Compiled FISH and oaCGH Log2 data
CFA1 CFA6 CFA10 CFA12 CFA13 CFA19 CFA21 CFA33 CFA36 CFA38 CFA11 p
K9TCC-Pu-An
oaCGH Log2 −0.40 −0.50 2.94 −0.30 1.23 −0.96 −0.40 −0.60 0.60 1.20 0.00 0.49
FISH Count 2.90 3.90 10.80 3.00 8.30 1.97 2.92 3.30 8.81 7.03 3.76
FISH Log2 −0.37 0.05 1.52 −0.33 1.14 −0.93 −0.36 −0.19 1.23 0.90 0.00
K9TCC-Pu-In
oaCGH Log2 −0.40 −0.53 1.40 0.00 0.52 −1.00 −0.40 −0.60 0.40 0.43 0.00 0.32
FISH Count 3.40 3.73 11.00 4.07 5.62 2.50 4.10 3.00 6.87 6.77 3.79
FISH Log2 −0.16 −0.02 1.54 0.10 0.57 −0.60 0.11 −0.34 0.86 0.84 0.00
K9TCC
oaCGH Log2 0.13 −0.30 2.40 −1.00 0.96 −1.00 0.00 0.07 0.00 0.60 0.00 0.65
FISH Count 2.23 2.10 6.96 1.13 3.96 1.06 2.00 2.60 1.97 2.03 1.97
FISH Log2 0.18 0.09 1.82 −0.80 1.01 −0.89 0.02 0.40 0.00 0.04 0.00
K9TCC-Pu-Mx
oaCGH Log2 0.04 0.19 0.04 −0.20 0.90 0.00 −0.20 −0.22 1.90 1.10 0.00 0.76
FISH Count 3.80 4.80 4.30 2.88 6.61 3.90 2.50 3.57 11.97 5.71 3.88
FISH Log2 −0.03 0.31 0.15 −0.43 0.77 0.01 −0.63 −0.12 1.63 0.56 0.00
K9TCC-Pu-Sh
oaCGH Log2 −1.00 −1.30 1.30 −1.00 0.93 0.00 −1.80 −1.05 0.20 −1.30 0.00 1.00
FISH Count 1.93 1.25 6.33 1.47 5.34 3.14 0.64 2.00 6.19 2.13 3.68
FISH Log2 −0.93 −1.56 0.78 −1.32 0.54 −0.23 −2.52 −0.88 0.75 −0.79 0.00
Log2 ratio values obtained from oaCGH analysis of cell lines and calculated by raw FISH data are shown. For each cell line, a Mann–Whitney U test was conducted
to evaluate consistency of data between both analysis methods (p < 0.05). In all cases, the mean Log2 ratio obtained from oaCGH and FISH was not significantly
different (p > 0.32 in all cases), validating oaCGH results and demonstrating the utility of oaCGH in large-scale copy number analysis. Bolded Log2 ratios
demonstrate significant gains or losses (Log2 < −0.234 or Log2 > 0.2)
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gains on CFA13. In primary tumors, however, GISTIC
analysis implicated numerous regions, including the
majority of those seen in the cell lines. These results not
only emphasize the importance of genes highlighted by
GISTIC analysis, but may also suggest that a number of
the mutations seen in the primary tumor may be passen-
ger mutations unessential for tumor maintenance in the
cell lines. Thus, we may be able to utilize the less geno-
mically complex cell lines to hone in on driver muta-
tions crucial for UC pathogenesis and progression.
In addition to major chromosome aberrations,
chromothriptic-like events represent another manifest-
ation of copy number change. First described in 2011,
chromothriptic-like events represent small genomic re-
gions comprised of numerous adjacent and alternating
copy number changes [19, 20]. Chromothriptic-like
events were previously found to be prevalent throughout
the genome of primary canine UC, particularly on
CFA36, 10, 16, 4 and 7 [4]. Similarly, the cell lines show
a high frequency and number of chromothriptic-like
events throughout the genome, with 21 of 39 chromo-
somes demonstrating recurrent chromothriptic-like
events in at least two cell lines. Among these are all of
those observed at high frequency in primary tumors, ex-
cept CFA16. The prevalence of chromothriptic-like
events in the cell line genomes suggests inherent gen-
ome instability along with a massive chromosome shat-
tering event. For example, tandem duplications observed
on CFA10, 36, and 38, as well as translocations among
these chromosomes (t(36;38)), may have arisen due to
such chromothriptic events early in or leading to neo-
plastic transformation. Although arising from an un-
known etiology, current hypotheses of chromothripsis in
cancer implicate mutagenic exogenous compounds,
which induce double-stranded DNA breaks throughout
the genome, and chromosome missegregation [21, 22].
This type of chromosome shattering can lead to massive
regional amplification, as well as losses and translocations,
due to improper chromosome rejoining. Particularly when
considering the potential etiology of risk-associated
Fig. 3 Structural Aberrations exist in oaCGH-flagged Regions. Tandem duplications, translocations, and fusions were noted throughout the karyotypes.
According to oaCGH, CFA 10 (BAC probe CHORI-82:326H08; Cy5-labeled) shows a sharp spike of gain in the probed region (MDM2). FISH shows this
spike might be attributed to tandem duplications of the locus along the chromosome (a). CFA 13 (BAC probe CHORI-82:BAC 186J06; Aqua-labeled)
appears as two fused copies (b) multiple times within a karyotype, in addition to what appear to be normal copies, leading to an overall
gain. Tandem duplication and locus translocation are both observed on chromosomes 36 (BAC probe CHORI-82:199F16, Cy5-labeled)/38
(BAC probe CHORI-82:328D10, Gold-labeled) (c). The pattern shows an overlap of duplication, in which a copy of the CFA 36 locus is
flanked by CFA 38
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carcinogenic compounds, chromothripsis is a hugely
interesting phenomenon in UC.
In addition to validating oaCGH-called aberrations,
the ability to perform metaphase FISH on the cell lines
allowed us to explore karyotypic reorganization occur-
ring in canine UC, including recurrent tandem duplica-
tions responsible for CFA36 amplification and a CFA13
duplication and centromeric fusion often responsible for
increases in CFA13. In our cell line analyses, copies of
CFA10, 36, and 38 per cell were often too numerous to ac-
curately count (>10-30 clearly distinguishable signals, par-
ticularly in K9TCC-Pu-Mx). Furthermore, in all cell lines,
abnormally metacentric chromosomes were seen, suggest-
ing prior mitotic dysfunction and/or breakage-fusion-
bridge cycles and leading to the formation of new hybrid
chromosomes.
The hyperdiploid karyotype of the cell lines, excluding
K9TCC, further confirmed previous findings that canine
UCs are often tetraploid (>50 % of UCs) [23]. Since
oaCGH is blind to ploidy, the correlation between
oaCGH status and copy number requires knowledge of
ploidy status, making a copy number neutral control
critical to appropriate copy number interpretation.
CFA11 was identified as copy number neutral using
oaCGH values and FISH analysis; CGH values suggestive
of neither a loss nor gain (Log2 ≈ 0 for all cell lines) and
chromosome structure appeared normal. In polyploid
cell lines, four copies of CFA11 were consistently ob-
served, supporting a tetraploid genome. Similarly, when
oaCGH implied a copy number loss, one to three copies
were observed, showing a relative, but often not abso-
lute, loss of genetic material. In the case of CFA19, only
in diploid K9TCC did the chromosome count consist-
ently reflect an absolute copy number loss (n < 2). Rela-
tive to a duplicated genome, however, two copies of CFA
19 (K9TCC-PU-An) reflected a loss rather than a normal
diploid number of Log2 = 0.
Cells were repeatedly passaged (>10 passages) in order
to determine the stability of the UC genomic profile over
time. Little change was evident in oaCGH profiles or
chromosome structure of cell lines after passaging cells
from early to mid-late stage. Only three regions on
CFA1, 2, and 9 were significantly different between early
and late passages, representing less than 0.006 % of the
entire genome in length. Although the region on CFA9
contains no known genes, the regions on CFA1 and 2
contain genes potentially relevant to the culture environ-
ment: insulin-like growth factor 2 receptor (IGF2R,
CFA1) and a protocadherin cluster (PCDH, CFA2).
IGF2R and PCDH are both potential adaptations to the
culture environment, allowing improved utilization of
media sugars and improving culture flask adhesion, re-
spectively. Nevertheless, such few aberrations acquired
over 10+ passages represent a very minor effect of re-
peated passage and cell culture. This characteristic of
the cell lines allows experimentation and analysis over
time without concern of culture-induced changes, a
valuable feature for translational studies.
We should note that several factors might influence our
results. One is that cell lines are ex vivo models. Thus,
some aberrations detected in cell lines may be due to the
altered culture environment. We were unable to analyze
the primary tumor from which the cell lines were de-
rived, precluding our ability to detect initial culture-
related genomic changes. Secondly, since oaCGH is a
cell population-based analysis, it is plausible that rare
aberrations evaded detection by oaCGH, but would
become more prominent with continued neoplastic
cell proliferation. However, our cell lines sustained
the major copy number changes seen in primary
tumors, even after ten or more passages, leading us
to conclude cell lines represent a good model for UC
in vitro.
Factors incriminated in the development of UC in-
clude exposure to cyclic amines, including carcinogens
in cigarette smoke, estrogen, and cyclophosphamide, as
























Fig. 4 Gene expression arrays, qRT-PCR, and oaCGH results support
one another and suggest a role of genomic copy number on mRNA
levels. Seven differentially expressed genes located in copy number-
aberrant regions (see Table 3) were selected for qRT-PCR analysis to
validate microarray results. Correlation was very strong
(r = 0.96) between the two methods and direction of fold change
was in agreement for all genes, confirming the gene’s differential
expression is true. In addition, comparison of qRT-PCR and oaCGH
Log2 ratios revealed a strong correlation (r = 0.76), demonstrating
the impact of genomic gene dosage on mRNA levels
Shapiro et al. Canine Genetics and Epidemiology  (2015) 2:15 Page 10 of 14
analysis of genes underexpressed in the UC cell lines re-
vealed GO enrichment of genes essential to the metabolism
of such lipophilic cyclic compounds. Genes underexpressed
in the UC cell lines were also enriched in metabolic KEGG
pathways, most notably pathways involved in xenobiotic
metabolism. Decreased expression of metabolic genes sug-
gests that toxic compounds are not being handled properly
by the bladder epithelium, potentially leading to a buildup
of corrosive compounds in the urine and increased expos-
ure of the urothelium to carcinogens. In particular,
carboxylesterase-1 (CES-1; CFA2; fold change = −633.5) is
involved in metabolism of organophosphate and pyrethroid
insecticides, both associated with UC development [28–30].
Similarly, decreased to undetectable levels of urothelial
CES1 are associated with UC in humans [31]. In addition,
CES enzymatic activity is highly variable among human in-
dividuals and may be associated with differences in canine
breed susceptibilities [32, 33].
Of further interest, Cytochrome P450 2C19 (CYP2C19;
CFA28; fold change = −8.1) is a potentially relevant
metabolic gene central to the enriched cytochrome p450
KEGG pathway. CYP2C19 is one of the most important
cytochrome p450 enzymes and is responsible for the
metabolism of numerous cyclic amine xenobiotics, in-
cluding the pyrethroid-derivatives of hydantoin present
in common insecticides [34]. Similar to CES1, genetic
polymorphisms of CYP2C19 are associated with reduced
metabolic capacity in humans, suggesting similar phe-
nomena may occur among genetically distinct dog
breeds [35, 36]. Our data corroborate previous specula-
tions regarding the involvement of metabolic pathways
in canine UC development and highlights a need for
closer investigation.
Among genes overexpressed in the UC cell lines, GO
terms were enriched for DNA replication, recombin-
ation, and repair. Similarly, KEGG analysis highlighted
cell cycle regulator pathways, in which 4 % of genes with
expression five-fold above that of normal urothelium
were involved (1.8 % of all overexpressed genes). One of
the most prominent overexpressed genes in our data-
set and a key gene in DNA replication and cell cycle
regulation–PTTG1 (CFA4; fold change=+57.5). As a
result of its functions as a sister chromatid securin,
microtubule nucleation regulator, and AKT activator,
among others, PTTG1 overexpression potentiates
tumor proliferation and invasion, as well as chromo-
some instability [37–39]. Interestingly, activating mu-
tations in FGFR3, an upstream regulator of AKT
activity, are implicated in constitutive activation of
the AKT pathway commonly seen in human UC [40].
PTTG1 has the potential to be a major driver of AKT
activation in canine UC, providing a valuable thera-
peutic target and highlighting pathway dysregulation
similarities in human and dog UC.
Our expression data also emphasized the potential
impact of chromosome copy number on gene dosage
and, therefore, gene expression. When analyzing genes
located in regions of copy number aberration, it was
shown that gene expression often varied directly with
copy number change (r = 0.76). DAVID chromosome
analysis showed enrichment of underexpressed genes on
CFA19, which is frequently lost in UC cell lines. CFA 19
contains the gene for histamine N-methyltransferase
(HNMT), a gene highly under expressed in our cell lines
(fold change = −29.6). Although unreported in bladder
cancer, reduced HNMT transcription has been reported
in other human carcinomas and is posited to be involved
in tumorigenesis [41]. Decreased levels of HNMT lead to
local increases of angiogenesis-promoting PTGS2 (COX2;
CFA7). PTGS2 levels are increased in both canine and hu-
man UC, and this gene is similarly overexpressed in our
cell line data (fold change = +76.9), providing a further
mechanistic role for COX-2 inhibitors in UC treatment
[42, 43]. Additionally, COX2 is a downstream effector of
an activated AKT pathway, again suggesting a conserva-
tion of AKT overactivation in both canine and human UC
development.
Similarly, gain of CFA 13 led to chromosome en-
richment of overexpressed genes (4.7 % of overex-
pressed genes), including the oncogenic transcription
factor MYC. Responsible for expediting the cell cycle
and bypassing critical checkpoints, MYC has been im-
plicated in numerous human cancers, including blad-
der cancer [44] and is overexpressed cell lines (fold
change = +8.5), along with downstream targets cyclin
D1 and D2 (fold change = +2.2 and +14.2, respect-
ively). The increase in downstream targets suggests
amplified MYC is not only over transcribed, but also
translated and functionally active. Furthermore, our
expression data suggests a high level of conservation
in DEGs between human and canine UC (Table 6),
providing a potentially valuable model of the human
disease and reinforcing previous findings that canine
and human UC are molecularly, clinically, and histo-
pathologically similar.
Despite strong correlations between copy number
gain/loss and differential gene expression (Fig. 4), it is
not known if increased genomic dosage directly leads
to increased transcript levels. In fact, PABPC1, a gene
located in the region of shared high frequency gain
on HSA 8/CFA 13 in human and canine UC, was ac-
tually underexpressed (average fold change = −2.6) in
the cell lines [4]. However, PABPC1 is highly
expressed, at both mRNA and protein levels, in nor-
mal urothelium, potentially obscuring subtle differ-
ences in expression while reducing their physiologic
significance [45, 46]. Additionally, while human ex-
pression studies have shown relative overexpression of
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PABPC1 at the mRNA level, protein studies have
shown a relative decrease in protein, espousing the
need for protein evaluation alongside mRNA quantifi-
cation [47]. We cannot discount the importance of epi-
genetic factors in determining expression. In addition,
disruption of gene promoters and enhancers, as may occur
due to tandem duplication, deletion, and/or translocation,
may alter predicted gene expression. Post-transcriptional
gene regulation may also play a role due to possible al-
terations in silencing RNA. Regardless, it is reason-
able to assume genomic copy number plays a role in
determining corresponding mRNA levels.
Conclusions
The recurrence of specific genetic aberrations in UC em-
phasizes the importance of continued UC genomic re-
search, particularly in predisposed dog breeds with
reduced genetic variation and in association with prom-
inent carcinogenic risk factors. A treatment found to be
effective in canine cell lines, which then is effective in
dogs, increases the clinical predictive value of the cell
lines and, therefore, their value to biomedical research
[11]. The preservation of primary tumor aberrations in
the cell line model provides an accessible and accurate
means of performing genetic experiments in vitro, mak-
ing the cell lines a valuable resource for translational UC
research. Future research should involve utilizing the
UC cell lines in a functional manner to elucidate mecha-
nisms of UC pathogenesis.
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